Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2012-06-07 Transaction in Own Shar…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Aankoop van eigen aandelen in het kader van langetermijnincentives toegekend aan het personeel.pdf
Transaction in Own Shares Classification · 98% confidence The document is titled 'Aankoop van eigen aandelen in het kader van langetermijnincentives toegekend aan het personeel' (Purchase of own shares in the context of long-term incentives granted to staff). It explicitly details the date, price, and number of UCB shares bought back on the stock exchange and states these shares were delivered to staff who exercised options. This activity directly corresponds to the company buying back or selling its own shares, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it involves employee incentives, the core action reported is the share transaction itself.
2012-06-07 Dutch
UCB expands in Brazil
M&A Activity Classification · 99% confidence The document is a press release dated May 30, 2012, announcing a strategic partnership and acquisition where UCB acquires 51% of Meizler Biopharma in Brazil. It details business strategy, financial consolidation under IFRS, and includes forward-looking statements typical of corporate news. This type of announcement, detailing a significant business transaction (M&A activity), is best classified under the 'M&A Activity' category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), but specifically concerns a merger/takeover proposal/agreement.
2012-05-30 English
UCB en expansion au Brésil
M&A Activity Classification · 99% confidence The document is explicitly labeled as "UCB - Information réglementée" (UCB - Regulated Information) and details a significant corporate action: UCB acquiring a 51% stake in the Brazilian firm Meizler Biopharma. This announcement concerns a strategic partnership and acquisition, which falls under corporate financing or major transaction news. Since it is a press release announcing a specific, material event (M&A activity) rather than a routine periodic financial report (like 10-K or IR) or a general regulatory filing (RNS), the most appropriate category is M&A Activity (TAR). It is not a general Earnings Release (ER) or a comprehensive Interim Report (IR).
2012-05-30 French
UCB breidt uit in Brazilië
M&A Activity Classification · 99% confidence The document is a press release dated May 30, 2012, announcing a strategic partnership and acquisition where UCB acquires 51% of Meizler Biopharma in Brazil. This announcement details a significant corporate transaction involving M&A activity (acquisition/partnership) and financing implications (consolidation under IFRS). While it contains financial context (revenue figures, consolidation rules), its primary nature is announcing a major corporate development/transaction. This aligns best with the 'M&A Activity' category (TAR). It is not a full Annual Report (10-K), an Earnings Release (ER), or a comprehensive Interim Report (IR). It is a specific corporate action announcement.
2012-05-30 Dutch
Acquisition of own shares_ENG (17-05).pdf
Transaction in Own Shares Classification · 99% confidence The document explicitly details the acquisition of UCB shares by the company itself on specific dates and prices, stating it is 'In application of art. 207 of the Royal Decree executing the Company Code'. The title is 'Acquisition of own shares in the framework of employees' long-term incentive plans'. This directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS). Although it is a regulated information press release, the core subject matter is the share transaction itself, making POS a more specific and accurate classification than the general RNS.
2012-05-17 English
Acquisition of own shares_FR (17-05).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition d'actions propres dans le cadre de rémunérations variables à long terme du personnel" (Acquisition of own shares under long-term variable remuneration for personnel). It explicitly details the purchase of 80,000 UCB shares on specific dates (May 10, 11, and 14, 2012) and the price, stating these actions were delivered to personnel exercising stock options. This activity directly corresponds to the company buying back or issuing shares related to employee compensation plans, which falls under the definition of 'Transaction in Own Shares' (POS). Although it involves remuneration, the core action described is the transaction of shares by the company itself, making POS a more precise fit than DEF 14A (which focuses on compensation disclosure). It is not a general regulatory filing (RNS) because it describes a specific, reportable corporate action.
2012-05-17 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.